Atreca receives $6M for Immune Repertoire Capture tech for infectious diseases

Friday, September 28, 2012 11:47 AM

Atreca, a privately held biopharmaceutical company based in San Carlos, Calif., has formed a collaboration with the Bill & Melinda Gates Foundation to accelerate the discovery and development of novel vaccines and therapeutics for human infectious diseases.

"We are grateful to the Bill & Melinda Gates Foundation for its vision," said Tito A. Serafini, CEO, CSO and co-founder of Atreca. "This commitment from the foundation provides Atreca an opportunity to apply the company's Immune Repertoire Capture technology to meet key challenges in global health."

The foundation's investment establishes a long-term collaboration between the parties.  Atreca will apply its Immune Repertoire Capture technology in a particular set of infectious diseases and other conditions, and the company will share with the foundation the results for use in the discovery and development of vaccines, therapeutics and diagnostics to be deployed in a defined group of countries. In the first four years, the partnership will focus on at least three diseases identified: malaria, HIV/AIDS and tuberculosis.

Immune Repertoire Capture technology leverages next-generation sequencing to identify rapidly and comprehensively the set of functional antibodies produced in patients during an immune response. These antibodies both have utility themselves and can be employed to identify the targets of an immune response. Applied to human disease, Immune Repertoire Capture is an engine for the discovery and development of antibody-based therapeutics, vaccines, diagnostics and research reagents. 

Atreca recently licensed exclusive rights to the technology for all fields of use from Stanford University.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs